205 related articles for article (PubMed ID: 34979560)
1. A new murine model of Barth syndrome neutropenia links TAFAZZIN deficiency to increased ER stress-induced apoptosis.
Sohn J; Milosevic J; Brouse T; Aziz N; Elkhoury J; Wang S; Hauschild A; van Gastel N; Cetinbas M; Tufa SF; Keene DR; Sadreyev RI; Pu WT; Sykes DB
Blood Adv; 2022 Apr; 6(8):2557-2577. PubMed ID: 34979560
[TBL] [Abstract][Full Text] [Related]
2. Experimental models of Barth syndrome.
Pu WT
J Inherit Metab Dis; 2022 Jan; 45(1):72-81. PubMed ID: 34370877
[TBL] [Abstract][Full Text] [Related]
3. Tafazzin Mutation Affecting Cardiolipin Leads to Increased Mitochondrial Superoxide Anions and Mitophagy Inhibition in Barth Syndrome.
Petit PX; Ardilla-Osorio H; Penalvia L; Rainey NE
Cells; 2020 Oct; 9(10):. PubMed ID: 33096711
[TBL] [Abstract][Full Text] [Related]
4. The lipid environment modulates cardiolipin and phospholipid constitution in wild type and tafazzin-deficient cells.
Oemer G; Koch J; Wohlfarter Y; Lackner K; Gebert REM; Geley S; Zschocke J; Keller MA
J Inherit Metab Dis; 2022 Jan; 45(1):38-50. PubMed ID: 34494285
[TBL] [Abstract][Full Text] [Related]
5. Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.
Zegallai HM; Hatch GM
Mol Cell Biochem; 2021 Mar; 476(3):1605-1629. PubMed ID: 33415565
[TBL] [Abstract][Full Text] [Related]
6. Loss of tafazzin results in decreased myoblast differentiation in C2C12 cells: A myoblast model of Barth syndrome and cardiolipin deficiency.
Lou W; Reynolds CA; Li Y; Liu J; Hüttemann M; Schlame M; Stevenson D; Strathdee D; Greenberg ML
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Aug; 1863(8):857-865. PubMed ID: 29694924
[TBL] [Abstract][Full Text] [Related]
7. Cardiac and skeletal muscle defects in a mouse model of human Barth syndrome.
Acehan D; Vaz F; Houtkooper RH; James J; Moore V; Tokunaga C; Kulik W; Wansapura J; Toth MJ; Strauss A; Khuchua Z
J Biol Chem; 2011 Jan; 286(2):899-908. PubMed ID: 21068380
[TBL] [Abstract][Full Text] [Related]
8. A critical appraisal of the tafazzin knockdown mouse model of Barth syndrome: what have we learned about pathogenesis and potential treatments?
Ren M; Miller PC; Schlame M; Phoon CKL
Am J Physiol Heart Circ Physiol; 2019 Dec; 317(6):H1183-H1193. PubMed ID: 31603701
[TBL] [Abstract][Full Text] [Related]
9. Tafazzin deficiency impairs CoA-dependent oxidative metabolism in cardiac mitochondria.
Le CH; Benage LG; Specht KS; Li Puma LC; Mulligan CM; Heuberger AL; Prenni JE; Claypool SM; Chatfield KC; Sparagna GC; Chicco AJ
J Biol Chem; 2020 Aug; 295(35):12485-12497. PubMed ID: 32665401
[TBL] [Abstract][Full Text] [Related]
10. Clinical presentation and natural history of Barth Syndrome: An overview.
Taylor C; Rao ES; Pierre G; Chronopoulou E; Hornby B; Heyman A; Vernon HJ
J Inherit Metab Dis; 2022 Jan; 45(1):7-16. PubMed ID: 34355402
[TBL] [Abstract][Full Text] [Related]
11. A Drosophila model of Barth syndrome.
Xu Y; Condell M; Plesken H; Edelman-Novemsky I; Ma J; Ren M; Schlame M
Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11584-8. PubMed ID: 16855048
[TBL] [Abstract][Full Text] [Related]
12. Cardiolipin metabolism regulates expression of muscle transcription factor MyoD1 and muscle development.
Vo L; Schmidtke MW; Da Rosa-Junior NT; Ren M; Schlame M; Greenberg ML
J Biol Chem; 2023 Mar; 299(3):102978. PubMed ID: 36739949
[TBL] [Abstract][Full Text] [Related]
13. TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome.
Garlid AO; Schaffer CT; Kim J; Bhatt H; Guevara-Gonzalez V; Ping P
Gene; 2020 Feb; 726():144148. PubMed ID: 31647997
[TBL] [Abstract][Full Text] [Related]
14. Single Cell Transcriptomic Analysis in a Mouse Model of Barth Syndrome Reveals Cell-Specific Alterations in Gene Expression and Intercellular Communication.
Perera G; Power L; Larson A; Codden CJ; Awata J; Batorsky R; Strathdee D; Chin MT
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511352
[TBL] [Abstract][Full Text] [Related]
15. The Function of Tafazzin, a Mitochondrial Phospholipid-Lysophospholipid Acyltransferase.
Schlame M; Xu Y
J Mol Biol; 2020 Aug; 432(18):5043-5051. PubMed ID: 32234310
[TBL] [Abstract][Full Text] [Related]
16. Cardiolipin deficiency in Barth syndrome is not associated with increased superoxide/H
Goncalves RLS; Schlame M; Bartelt A; Brand MD; Hotamışlıgil GS
FEBS Lett; 2021 Feb; 595(3):415-432. PubMed ID: 33112430
[TBL] [Abstract][Full Text] [Related]
17. FGF21 and GDF15 are elevated in Barth Syndrome and are correlated to important clinical measures.
Liu O; Chinni BK; Manlhiot C; Vernon HJ
Mol Genet Metab; 2023 Nov; 140(3):107676. PubMed ID: 37549445
[TBL] [Abstract][Full Text] [Related]
18. Current and future treatment approaches for Barth syndrome.
Thompson R; Jefferies J; Wang S; Pu WT; Takemoto C; Hornby B; Heyman A; Chin MT; Vernon HJ
J Inherit Metab Dis; 2022 Jan; 45(1):17-28. PubMed ID: 34713454
[TBL] [Abstract][Full Text] [Related]
19. Genetic modifiers modulate phenotypic expression of tafazzin deficiency in a mouse model of Barth syndrome.
Wang S; Yazawa E; Keating EM; Mazumdar N; Hauschild A; Ma Q; Wu H; Xu Y; Shi X; Strathdee D; Gerszten RE; Schlame M; Pu WT
Hum Mol Genet; 2023 Jun; 32(12):2055-2067. PubMed ID: 36917259
[TBL] [Abstract][Full Text] [Related]
20. Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation.
Gonzalvez F; D'Aurelio M; Boutant M; Moustapha A; Puech JP; Landes T; Arnauné-Pelloquin L; Vial G; Taleux N; Slomianny C; Wanders RJ; Houtkooper RH; Bellenguer P; Møller IM; Gottlieb E; Vaz FM; Manfredi G; Petit PX
Biochim Biophys Acta; 2013 Aug; 1832(8):1194-206. PubMed ID: 23523468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
